Allogene Q2 net loss $50.9M; highlights ALPHA3 trial progress and ALLO-329 autoimmune initiation

Allogene Therapeutics, Inc.

2025-Q2 EPS reported -$0.51 vs consensus -$0.28 ▼ miss (-82.8%)

Net loss of $50.9M ($0.23/share) for Q2 2025; cash and investments $302.6M as of June 30, 2025.
Pivotal ALPHA3 trial for cema-cel in LBCL proceeding as randomized two-arm study; futility analysis on track for 1H 2026.
Phase 1 RESOLUTION trial with ALLO-329 initiated in rheumatology autoimmune diseases; proof-of-concept data expected 1H 2026.
ALLO-316 completed Phase 1b enrollment in RCC; FDA aligned on pivotal trial design, partnership discussions possible.
Cash runway projected into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP OpEx ~$230M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.